Efficacy of Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen After Cesarean Section
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Jun 24, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how effective different pain relief methods are after a cesarean section (a surgical procedure to deliver a baby). Specifically, it will compare the use of intravenous acetaminophen alone with a combination of acetaminophen and ibuprofen (a common over-the-counter pain reliever). The goal is to find out which method provides better pain relief for women recovering from this surgery.
To participate in this trial, women must be scheduled for an elective cesarean section and be at least 37 weeks pregnant. However, some women will not be eligible, including those having emergency cesarean sections, those who are pregnant with multiples (like twins), or those with certain medical conditions such as liver or kidney disease. If eligible, participants will receive one of the two pain relief methods after their surgery and will help researchers learn more about managing pain effectively after cesarean deliveries.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients scheduled for elective cesarean section
- • Gestational age \> 37+0 weeks
- Exclusion Criteria:
- • Emergency cesarean section
- • Multiple pregnancy (e.g. twins, triplets)
- • Body weight \< 50 kg
- • Preeclampsia
- • History of hypersensitivity to acetaminophen or ibuprofen
- • History of upper gastrointestinal tract bleeding or gastric ulcer
- • Underlying liver disease
- • Underlying kidney disease or GFR \< 90 mL/min/1.73m2
- • Heart failure or severe hypertension
- • History of asthma
- • Chronic use of barbital or tricyclic antidepressants
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported